1381PDGefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study. (23rd October 2018) - Yang, J C-H; Cheng, Y; Murakami, H; Yang, P-C; He, J; Nakagawa, K; Kang, J H; Kim, J-H; Wnag, X; Enatsu, S; Puri, T; Orlando, M